FDA Approves Botox for Overactive Bladder

When patients don't respond to standard treatments

TUESDAY, Jan. 22 (HealthDay News) -- U.S. Food and Drug Administration approval of Botox (onabotulinumtoxinA) has been expanded to include adults with overactive bladder who don't respond to anticholinergics.

In a clinical study, people treated with Botox after 12 weeks had urinary incontinence 1.6 to 1.9 times less per day than people treated with a placebo, the FDA said.

The most common adverse reactions recorded during the study included urinary tract infection, painful urination, and urinary retention. People who develop urinary retention may have to use a catheter until the situation resolves, the agency said.

Botox has been approved for several other uses, notably to treat facial wrinkles. The product is made by Allergan Inc., based in Irvine, Calif.

More Information

Copyright © 2013 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Abdominal Pain: An Approach to a Challenging Diagnosis
AACN Advanced Critical Care, July/September 2014
Free access will expire on October 13, 2014.


HIPAA Compliance Practice Tips
Professional Case Management, July/August 2014
Free access will expire on September 29, 2014.


Follow the leader: How does “followership” influence nurse burnout?
Nursing Management, August 2014
Free access will expire on September 29, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events